Bevacizumab for the management of low-grade serous ovarian cancer in first-line and recurrent disease

被引：0
|
作者：
Van Den Kieboom, Natalia [1 ]
Ottenbourgs, Tine [2 ]
Van Nieuwenhuysen, Els [3 ,4 ]
机构：
[1] Katholieke Univ Leuven, Leuven Canc Inst, Dept Gynaecol & Obstet, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven Canc Inst, Lab Gynaecol Oncol, Leuven, Belgium
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Luxembourg Gynaecol Oncol Grp BGOG, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EV338/#101
引用
收藏
页码：A258 / A259
页数：2
相关论文
共 50 条
  • [41] The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
    Crane, Erin K.
    Sun, Charlotte C.
    Ramirez, Pedro T.
    Schmeler, Kathleen M.
    Malpica, Anais
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 25 - 29
  • [42] Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
    Hacker, Kari E.
    Uppal, Shitanshu
    Johnston, Carolyn
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (09): : 1175 - 1182
  • [43] Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer
    Nobre, Silvana Pedra
    Peplinski, Rebekah
    Schillo, Jacob
    Ulmer, Keely
    Riordan, Jesse
    Dupuy, Adam
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S305 - S305
  • [44] MEK inhibition for low-grade serous ovarian cancer: are we there yet?
    Scaranti, Mariana
    Mathias-Machado, Maria Cecilia
    Guo, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 155 - 156
  • [45] Advances in precision therapy of low-grade serous ovarian cancer: A review
    Wang, Qing
    Cao, Sheng-Han
    Li, Yan-Yu
    Zhang, Jing-Bo
    Yang, Xin-Hui
    Zhang, Bei
    MEDICINE, 2024, 103 (17) : E34306
  • [46] BinimetinibAcquired resistance in low-grade serous ovarian cancer: case report
    Reactions Weekly, 2020, 1789 (1) : 67 - 67
  • [47] Stage I low-grade serous ovarian cancer: Is there a benefit to chemotherapy?
    Vue, Nujsaubnusi
    Horne, Zachary
    Crafton, Sarah
    Krivak, Thomas
    Miller, Eirwen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S286 - S286
  • [48] New therapeutic opportunities for women with low-grade serous ovarian cancer
    Moujaber, Tania
    Balleine, Rosemary L.
    Gao, Bo
    Madsen, Ida
    Harnett, Paul R.
    DeFazio, Anna
    ENDOCRINE-RELATED CANCER, 2022, 29 (01) : R1 - R16
  • [49] KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma
    Tsang, Yvonne T.
    Deavers, Michael T.
    Sun, Charlotte C.
    Kwan, Suet-Yan
    Kuo, Eric
    Malpica, Anais
    Mok, Samuel C.
    Gershenson, David M.
    Wong, Kwong-Kwok
    JOURNAL OF PATHOLOGY, 2013, 231 (04): : 449 - 456
  • [50] Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?
    Vineyard, Marisa A.
    Daniels, Molly S.
    Urbauer, Diana L.
    Deavers, Michael T.
    Sun, Charlotte C.
    Boerwinkle, Eric
    Bodurka, Diane C.
    Gershenson, David M.
    Crawford, Jessica
    Lu, Karen H.
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 229 - 232
12345